Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 5/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39984 | 0.83 | ALDH1A1 (0.63) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL11341809 | 0.80 | MAP2 (0.69) | MAP2GPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL39977 | 0.78 | MAP2 (0.71) | MAP2GPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL39881 | 0.75 | CNR2 (0.47) | MAP2ALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL42364 | 0.74 | MAP2 (1.00) | MAP2GPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL3037898 | 0.73 | MAP2 (0.63) | MAP2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL39929 | 0.72 | MAP2 (0.61) | MAP2GPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL9457640 | 0.72 | MAP2 (0.65) | MAP2GPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL6921821 | 0.72 | MAP2 (0.65) | MAP2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL27372699 | 0.70 | MAP2 (0.63) | MAP2GPR35ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| WO-2010119984-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | IDO1, TPH1, AHR | MAP2 1030/4885GPR35 814/4885METAP2 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.